Comparative Effectiveness of Symbicort vs. Advair Among COPD Patients
Information source: AstraZeneca
ClinicalTrials.gov processed this data on August 23, 2015 Link to the current ClinicalTrials.gov record.
Condition(s) targeted: COPD
Phase: N/A
Status: Completed
Sponsored by: AstraZeneca
Summary
This study is intended to evaluate treatment effectiveness of BFC compared to FSC in COPD
patients new to ICS/LABA combination therapy.
Clinical Details
Official title: A U.S. Retrospective Database Analysis Evaluating the Comparative Effectiveness of Budesonide/Formoterol (BFC) vs. Fluticasone/Salmeterol (FSC) Combination in Patients With COPD.
Study design: Observational Model: Cohort, Time Perspective: Retrospective
Primary outcome: Rate of COPD exacerbation
Secondary outcome: COPD exacerbation rate sensitivity and subgroup analysesCOPD respiratory medication use COPD related healthcare utilization All-cause utilization All- cause and COPD related healthcare costs Treatment patterns and adherence Treatment modification COPD exacerbation rate sensitivity analysis
Eligibility
Minimum age: 40 Years.
Maximum age: N/A.
Gender(s): Both.
Criteria:
Inclusion Criteria:
- Continuous health plan enrollment for 12 months before and after index Rx, at least
one prescription for BFC or FSC during intake period, naive to ICS/LABA therapies in
year prior to first prescription claim, COPD diagnosis, aged 40 or over at time of
first prescription.
Exclusion Criteria:
- ICS/LABA combination during pre-index period, patients with a claim for BFC and FSC
on the same day, patients diagnosed with cancer, patients with long-term OCS
medication use during pre-index period.
Locations and Contacts
Additional Information
Starting date: August 2013
Last updated: May 14, 2014
|